Get started

Financials · OVID

Ovid Therapeutics Inc. (OVID) financials

For the twelve months ended Jun 30, 2026, Ovid Therapeutics Inc. reported $1.58M of revenue and -$34.49M of net income.

Revenue, TTM
$1.58M
Revenue growth, YoY
-76.2%
Net income, TTM
-$34.49M
Net margin
-2178.9%
Cash
$11.33M
P/S
351.61
Market cap
$556.6M
Annual revenue$7.25M
FY2020FY2025
Annual net income-$17.41M
FY2016FY2025
Annual free cash flow-$38.33M
FY2016FY2025

OVID revenue and earnings growth

OVID revenueQ2 2026$733.0K

Quarter YoY
-88.3%
FY YoY
13x
5Y CAGR
-10.5%

OVID revenue was $733.0K in fiscal Q2 2026 (ended Jun 30, 2026), down 88.3% from a year earlier. For the full fiscal 2025 it was $7.25M, up about 13-fold from fiscal 2024. Compound annual growth was -10.5% over 5 years. It rose in 3 of the last 5 fiscal years.

OVID net incomeQ2 2026-$15.01M

OVID net income was -$15.01M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$4.68M a year earlier. For the full fiscal 2025 it was -$17.41M, compared with -$26.43M in fiscal 2024.

OVID free cash flowQ4 2025-$10.41M

OVID free cash flow was -$10.41M in fiscal Q4 2025 (ended Dec 31, 2025), compared with -$10.03M a year earlier. For the full fiscal 2025 it was -$38.33M, compared with -$56.03M in fiscal 2024.

Export CSV

Income statement

Income statement
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Revenue$7.25M$566.0K$392.0K$1.50M$208.38M$12.62M----
Research and development$25.58M$36.77M$28.59M$24.62M$46.94M$63.42M$42.16M$33.79M$49.97M$9.59M
Selling, general and admin$24.11M$25.68M$31.09M$32.43M$37.23M$30.63M$19.25M$19.14M$15.04M$12.95M
Operating income-$42.44M-$61.88M-$59.28M-$55.55M$124.21M-$81.43M-$61.41M-$52.93M-$65.01M-$22.54M
Pre-tax income-$17.41M-$26.43M-$52.34M-$54.17M$124.16M-$81.04M----
Income tax$0$0$0$0$1.33M$0$0$0$0-
Net income-$17.41M-$26.43M-$52.34M-$54.17M$122.83M-$81.04M-$60.46M-$51.98M-$64.81M-$22.41M
EPS, basic---$0.74-$0.77$1.78-$1.39--$2.11-$3.35-$2.28
EPS, diluted---$0.74-$0.77$1.76-$1.39--$2.11-$3.35-$2.28
Diluted shares--70.6M70.4M68.1M58.5M-24.6M19.3M9.8M

Balance sheet

Balance sheet
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Cash and equivalents$13.15M$28.23M$28.97M$46.80M$189.73M$72.03M$41.90M$36.49M$87.13M$51.94M
Current assets$74.37M$55.94M$109.60M$131.38M$190.48M$74.84M$79.81M$44.27M$88.59M$52.41M
Total assets$150.93M$92.17M$144.03M$155.27M$194.54M$75.93M$80.84M$47.65M$89.46M$53.03M
Current liabilities$8.29M$10.52M$11.47M$6.99M$14.80M$22.06M$10.53M$8.84M$6.02M$3.73M
Total liabilities$20.27M$23.94M$56.23M$22.99M$14.80M$32.29M$10.82M$8.84M--
Shareholders' equity$130.66M$68.23M$87.80M$132.27M$179.75M$43.63M$70.02M$38.81M$83.44M$49.29M

Cash flow

Cash flow
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Operating cash flow-$38.33M-$55.96M-$45.78M-$55.23M$118.61M-$51.58M-$51.09M-$45.56M-$31.47M-$17.80M
Capital expenditures$0$71.0K$40.0K$1.22M$184.0K$127.2K$57.2K$33.9K$38.9K$30.4K
Free cash flow-$38.33M-$56.03M-$45.82M-$56.45M$118.43M-$51.71M-$51.15M-$45.59M-$31.51M-$17.83M
Investing cash flow-$49.85M$54.59M-$2.58M-$87.88M-$1.82M$34.65M-$30.04M-$5.36M-$47.4K-$189.0K
Financing cash flow$75.21M$622.0K$30.54M$180.7K$904.1K$47.07M$86.54M$286.1K$66.70M-$13.7K
Stock-based compensation$4.81M$6.28M$7.29M$6.56M$5.05M$7.53M$5.21M$7.06M$6.40M$3.64M
Depreciation and amortization$273.0K$613.0K$568.0K$512.5K$237.1K$306.8K$255.0K$141.7K$80.3K$56.5K

Key ratios

Key ratios
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Revenue growth, YoY1181.3%44.4%-73.9%-99.3%1551.6%-----
Operating margin-585.2%-10933.7%-15122.7%-3696.4%59.6%-645.4%----
Net margin-240.1%-4670.1%-13351.8%-3604.7%58.9%-642.3%----
Free cash flow margin-528.6%-9898.8%-11689.0%-3756.6%56.8%-409.8%----
Return on equity-13.3%-38.7%-59.6%-41.0%68.3%-185.7%-86.3%-134.0%-77.7%-45.5%
Return on assets-11.5%-28.7%-36.3%-34.9%63.1%-106.7%-74.8%-109.1%-72.4%-42.3%
Current ratio8.975.329.5518.7912.873.397.585.0114.7114.04

Source: XBRL data Ovid Therapeutics Inc. files with the SEC, latest filing dated Aug 13, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.

* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.

Per-share figures are as filed. The filings show no stock split in these periods.

EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.

OVID peers

CompanyRevenueGrowthNet incomeNet marginMarket cap
OVID$1.58M-76.2%-$34.49M-2178.9%$556.6M
LLY$86.46B+45.5%$27.58B31.9%$1.33T
JNJ$99.33B+7.8%$16.09B16.2%$679.13B
ABBV$66.01B+10.7%$10.34B15.7%$518.44B
MRK$67.38B+4.9%$2.45B3.6%$366.73B
NVS$54.53B+8.4%$13.98B25.6%$312.35B
AZN$58.74B+8.6%$10.22B17.4%$293.69B
ABT$48.23B+10.0%$4.70B9.7%$191.40B
NVODKK 309.06B+6.4%DKK 102.43B33.1%$183.23B

OVID FAQ

6 questions
  • What is OVID revenue?
    Ovid Therapeutics Inc. (OVID) reported $1.58M of revenue for the twelve months ended Jun 30, 2026. That is down 76.2% from the year before. Revenue for fiscal 2025 was $7.25M.
  • Is OVID profitable?
    No. Ovid Therapeutics Inc. reported a net loss of $34.49M for the twelve months ended Jun 30, 2026.
  • How much cash and debt does OVID have?
    Ovid Therapeutics Inc. reported $11.33M in cash and cash equivalents on its most recent balance sheet in SEC filings.
  • How fast is OVID revenue growing?
    Ovid Therapeutics Inc.'s revenue changed 13x in fiscal 2025, to $7.25M. Its compound annual growth rate was -10.5% over 5 years.
  • When did OVID last report financial results?
    The latest statements here come from Ovid Therapeutics Inc.'s 10-Q filed on Aug 13, 2026, covering the period ended Jun 30, 2026.
  • Where does this OVID financial data come from?
    Quantisnow builds these statements from the structured XBRL data Ovid Therapeutics Inc. files with the SEC. It is provided for information only and is not investment advice.